STOK250117P20000
- 0.00
- 0.000.00%
Stoke Therapeutics Newsroom
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Express News | Form 144 | Stoke Therapeutics(STOK.US) Insider Proposes to Sell 23.18 Million in Common Stocks
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $24
Stoke Therapeutics Initiated at Buy by Chardan Capital
Stoke Therapeutics Price Target Announced at $24.00/Share by Chardan Capital
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth
Stoke Therapeutics (NASDAQ:STOK) Pulls Back 9.1% This Week, but Still Delivers Shareholders Impressive 136% Return Over 1 Year
Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 13,945 Shares
Express News | Cantor Fitzgerald Reiterates Overweight on Stoke Therapeuticsto Overweight
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics: Promising Developments in Seizure Treatment Bolster Buy Rating
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $29
Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)
Stoke Therapeutics Reports Durable Seizure Control With Zorevunersen in Dravet Patient
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
GeneDx Announces Biogen, Praxis Precision Medicines And Stoke Therapeutics As The Founding Partners To Its Patient Access Program For Pediatric Epilepsy, Which Provides Access To Whole Exome Sequencing.
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients With New Partners
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday